How does publishing treatment guidelines Open Access (OA) impact on the potential for use by physicians? In this latest research story, Dr. Daniel Cameron reflects on the reaction to his evidence-based guidance on Lyme disease, and its worldwide impact and application.
“Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease” published in Expert Review of Anti-infective Therapy.
Published OA in July 2014.
Altmetric score: 112* (scored in the top 5% of all research outputs on Altmetric)
Our treatment guidelines article, Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease, was published OA in the journal Expert Review of Anti-infective Therapy in 2014 and had been downloaded more than 107,000 times by April 2016.
“…adopted the GRADE system as its basis for its evidence assessment”
These Lyme disease guidelines were developed because far too many individuals develop chronic complications including Lyme encephalopathy, chronic neurologic Lyme disease and post treatment Lyme disease. ILADS adopted the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system as its basis for its evidence assessment and development of recommendations, to ensure a transparent and trustworthy guideline process.
“…incredibly important to doctors and their patients”
Publishing ILADS’s evidence based treatment guideline for Lyme disease has been incredibly important to doctors and their patients. OA provides doctors and their patients who do not belong to large universities or institutions access to their transparent, peer reviewed evidence-based guidelines.
“Dissemination of practice guidelines encouraged access to evidence…”
As a way to highlight the guidelines, the International Lyme and Associated Diseases Society (ILADS) issued a press release in August 2015, posted the guidelines on their website and presented them at their October professional conference, and discussed the guidelines via social media. Dissemination of practice guidelines encouraged access to evidence to improve patient outcomes. The 107,000 downloads and Altmetric data demonstrates that the ILADS guidelines have been shared around the world.
Dr. Daniel Cameron graduated with degrees in Medicine and Epidemiology from the University of Minnesota followed by residencies at both Beth Israel Medical Center and Mt. Sinai School of Medicine in New York City. He has pioneered the field of clinical epidemiology in Lyme disease as an author of the 2004 and 2014 ILADS evidence based treatment guidelines, analytic reviews, and clinical trials.
He has been treating patients with Lyme disease in his private practice in Mt. Kisco, New York. He regularly communicates by Blog and Facebook at http://www.DanielCameronMD.com, including this post reflecting on the guidelines and their dissemination.
*Data recorded 1/6/2016